Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking

Stock Track05-22

Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market.

The movement represents a recovery following several sessions of profit-taking pressure since the company's highly anticipated IPO debut on May 13. The public offering was oversubscribed by 2,282 times, and shares had retreated more than 15% from their post-listing high before today's upward move, suggesting capital is flowing back into the stock after the recent correction.

Impact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies. Its core product, senaparib, a PARP1/2 inhibitor, received approval in China for first-line maintenance treatment of ovarian cancer in January and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107678797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 11:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107678797","market":"nz","top_or_hot":-1,"title":"Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking","media":"Stock Track","content":"<p>Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market.</p>\n<p>The movement represents a recovery following several sessions of profit-taking pressure since the company's highly anticipated IPO debut on May 13. The public offering was oversubscribed by 2,282 times, and shares had retreated more than 15% from their post-listing high before today's upward move, suggesting capital is flowing back into the stock after the recent correction.</p>\n<p>Impact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies. Its core product, senaparib, a PARP1/2 inhibitor, received approval in China for first-line maintenance treatment of ovarian cancer in January and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Impact Therapeutics-B Soars 15.59% Intraday in Strong Rebound After Post-IPO Profit-Taking\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-22 11:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market.</p>\n<p>The movement represents a recovery following several sessions of profit-taking pressure since the company's highly anticipated IPO debut on May 13. The public offering was oversubscribed by 2,282 times, and shares had retreated more than 15% from their post-listing high before today's upward move, suggesting capital is flowing back into the stock after the recent correction.</p>\n<p>Impact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies. Its core product, senaparib, a PARP1/2 inhibitor, received approval in China for first-line maintenance treatment of ovarian cancer in January and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1107678797","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107678797","pubTimestamp":1779419803,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market. The movement represents a recovery following several sessions of profit-taking pressure...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"个股轨迹|Impact Therapeutics-B盘中大涨15.59%IPO后获利回吐强劲反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market.\nThe movement represents a recovery following several sessions of profit-taking pressure since the company's highly anticipated IPO debut on May 13. The public offering was oversubscribed by 2,282 times, and shares had retreated more than 15% from their post-listing high before today's upward move, suggesting capital is flowing back into the stock after the recent correction.\nImpact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies. Its core product, senaparib, a PARP1/2 inhibitor, received approval in China for first-line maintenance treatment of ovarian cancer in January and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107678797","isCrawlerRequest":true}